Daniel Sullivan

发表

The creation of an integrated health-information platform: building the framework to support personalized medicine.

R. Wenham, W. Dalton, P. Jacobsen, 2012, Personalized medicine.

Use of the Total Cancer Care System to Enrich Screening for CD30-Positive Solid Tumors for Patient Enrollment Into a Brentuximab Vedotin Clinical Trial: A Pilot Study to Evaluate Feasibility

H. Dai, S. Eschrich, W. Dalton, 2017, JMIR research protocols.

Bortezomib salvage followed by a Phase I/II study of bortezomib plus high‐dose melphalan and tandem autologous transplantation for patients with primary resistant myeloma

W. Dalton, D. Sullivan, J. Pidala, 2012, British journal of haematology.

Verapamil suppresses the emergence of P‐glycoprotein‐mediated multi‐drug resistance

P. Meltzer, W. Dalton, B. Futscher, 1996, International journal of cancer.

Phase II study of pegylated liposomal doxorubicin, low‐dose dexamethasone, and lenalidomide in patients with newly diagnosed multiple myeloma

Ji‐Hyun Lee, W. Dalton, D. Sullivan, 2014, American journal of hematology.

The 2010 Health Care Reform Act: A Potential Opportunity to Advance Cancer Research by Taking Cancer Personally

David A Fenstermacher, T. Yeatman, W. Dalton, 2010, Clinical Cancer Research.

Patient Enrichment for Precision‐Based Cancer Clinical Trials: Using Prospective Cohort Surveillance as an Approach to Improve Clinical Trials

Jeffrey Ecsedy, M. Caligiuri, W. Dalton, 2018, Clinical pharmacology and therapeutics.

Identifying Dementia in the Primary Care Practice

P. Solomon, R. Deveaux, V. Calvo, 2000, International Psychogeriatrics.

A single supratherapeutic dose of ridaforolimus does not prolong the QTc interval in patients with advanced cancer

A. Tolcher, K. Papadopoulos, A. Patnaik, 2012, Cancer Chemotherapy and Pharmacology.

Impact of the 2010 Consensus Recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee

G. Rosner, S. Groshen, M. Ratain, 2015, Clinical Cancer Research.